Celcuity (NASDAQ:CELC) Receives "Buy" Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Celcuity (NASDAQ:CELC - Free Report) in a research note released on Friday morning,Benzinga reports. The brokerage currently has a $27.00 target price on the stock.

CELC has been the subject of several other research reports. Lifesci Capital started coverage on shares of Celcuity in a report on Monday, August 26th. They set an "outperform" rating and a $27.00 price objective for the company. Leerink Partners assumed coverage on Celcuity in a research report on Monday, July 22nd. They issued an "outperform" rating and a $29.00 price objective for the company. Needham & Company LLC restated a "buy" rating and set a $23.00 target price on shares of Celcuity in a report on Friday. Stifel Nicolaus raised their target price on Celcuity from $39.00 to $42.00 and gave the company a "buy" rating in a research note on Monday, October 7th. Finally, Leerink Partnrs upgraded shares of Celcuity to a "strong-buy" rating in a research report on Monday, July 22nd. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, Celcuity presently has a consensus rating of "Buy" and a consensus price target of $29.17.

Celcuity Price Performance

NASDAQ CELC traded down $1.45 during trading on Friday, reaching $12.66. 954,227 shares of the company traded hands, compared to its average volume of 279,872. Celcuity has a 1-year low of $11.51 and a 1-year high of $22.19. The company has a debt-to-equity ratio of 0.54, a quick ratio of 14.95 and a current ratio of 14.95. The stock's 50 day moving average price is $15.15 and its two-hundred day moving average price is $16.04. The company has a market cap of $468.80 million, a price-to-earnings ratio of -4.62 and a beta of 0.76.

Celcuity (NASDAQ:CELC - Get Free Report) last posted its earnings results on Wednesday, August 14th. The company reported ($0.62) earnings per share for the quarter, topping the consensus estimate of ($0.71) by $0.09. During the same quarter in the prior year, the business posted ($0.66) earnings per share. As a group, analysts anticipate that Celcuity will post -2.54 EPS for the current year.

Institutional Trading of Celcuity

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. nVerses Capital LLC acquired a new stake in shares of Celcuity during the 3rd quarter worth approximately $33,000. Prospera Private Wealth LLC acquired a new stake in Celcuity during the 3rd quarter worth $35,000. Values First Advisors Inc. bought a new stake in shares of Celcuity during the 3rd quarter valued at $86,000. Quest Partners LLC raised its position in shares of Celcuity by 31.3% during the 2nd quarter. Quest Partners LLC now owns 5,788 shares of the company's stock valued at $95,000 after acquiring an additional 1,379 shares during the last quarter. Finally, SG Americas Securities LLC acquired a new position in shares of Celcuity in the 3rd quarter valued at $119,000. 63.33% of the stock is currently owned by institutional investors and hedge funds.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.